
  
    
      
        Background_NNP
        The_DT cysteine-loop_JJ family_NN of_IN ligand_NN gated_JJ ion_NN channels_NNS
        (_( LGIC_NNP )_) is_VBZ comprised_VBN of_IN receptors_NNS with_IN pentameric_JJ quaternary_JJ
        structure_NN and_CC at_IN least_JJS two_CD ligand_NN binding_JJ sites_NNS present_JJ at_IN
        the_DT subunit_NN interfaces_NNS [_NN 1_CD 2_CD ]_NN ._. This_DT receptor_NN family_NN is_VBZ
        characterized_VBN by_IN the_DT presence_NN of_IN a_DT critical_JJ disulfide_NN loop_NN
        structure_NN within_IN the_DT binding_JJ site_NN and_CC an_DT integral_JJ ion_NN
        selective_JJ channel_NN ._. LGIC_NNP receptors_NNS are_VBP found_VBN in_IN both_DT the_DT
        peripheral_JJ and_CC central_JJ nervous_JJ systems_NNS ._. Members_NNS of_IN this_DT
        family_NN include_VBP the_DT acetylcholine_NN receptors_NNS [_NN 3_CD 4_CD ]_NN ,_, the_DT
        γ-amino_JJ butyric_JJ acid_NN type_NN A_DT receptor_NN (_( GABA_NNP 
        A_DT R_NN )_) [_NN 5_CD ]_NN ,_, and_CC the_DT glycine_NN receptor_NN
        (_( GlyR_NNP )_) [_NN 6_CD ]_NN ._.
        The_DT first_JJ subunit_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN was_VBD cloned_VBN in_IN 1991_CD [_NN 7_CD ]_NN ._. The_DT
        sequence_NN of_IN this_DT subunit_NN was_VBD shown_VBN to_TO be_VB highly_RB homologous_RB
        to_TO LGIC_NNP receptors_NNS and_CC thus_RB identified_VBD the_DT 5_CD -_: HT_NNP 
        3_CD R_NN receptor_NN as_IN another_DT member_NN of_IN this_DT
        superfamily_RB [_NN 7_CD 8_CD 9_CD ]_NN ._. Similar_JJ to_TO other_JJ LGIC_NNP receptors_NNS ,_,
        more_JJR than_IN one_CD subtype_NN has_VBZ been_VBN identified_VBN ._. Two_CD splice_NN
        variants_NNS of_IN an_DT A_DT subunit_NN (_( long_JJ and_CC short_JJ forms_NNS )_) ,_, and_CC a_DT
        single_JJ B_NNP subunit_NN have_VBP been_VBN cloned_VBN [_NN 10_CD 11_CD 12_CD 13_CD ]_NN ._. Both_DT
        the_DT long_JJ and_CC short_JJ forms_NNS of_IN the_DT A_DT subunit_NN are_VBP capable_JJ of_IN
        forming_VBG functional_JJ homomeric_JJ receptors_NNS [_NN 5_CD -_: HT_NNP 
        3_CD AL_NNP R_NNP and_CC 5_CD -_: HT_NNP 
        3_CD AS_NNP R_NNP ]_NN although_IN some_DT differences_NNS between_IN
        an_DT agonist_NN and_CC partial_JJ agonist_NN activity_NN have_VBP been_VBN observed_VBN
        [_NN 14_CD ]_NN ._. A_DT third_JJ subtype_NN is_VBZ formed_VBN by_IN a_DT combination_NN of_IN the_DT
        A_DT and_CC B_NNP subunits_NNS to_TO produce_VB a_DT heteromeric_JJ receptor_NN of_IN
        unknown_JJ stoichiometry_NN [_NN 10_CD ]_NN ._. Heteromeric_NNP receptors_NNS are_VBP
        pharmacologically_RB and_CC functionally_RB distinct_JJ from_IN the_DT
        homomeric_JJ 5_CD -_: HT_NNP 
        3_CD AL_NNP and_CC 5_CD -_: HT_NNP 
        3_CD AS_NNP receptors_NNS [_NN 11_CD ]_NN ._.
        5_LS -_: HT_NNP 
        3_CD Rs_NNP are_VBP distributed_VBN throughout_IN the_DT
        central_JJ and_CC peripheral_JJ nervous_JJ system_NN ,_, playing_VBG a_DT
        significant_JJ role_NN in_IN phenomenon_NN such_JJ as_IN anxiety_NN ,_, emesis_NNS and_CC
        alcoholism_NN ._. Antagonists_NNP to_TO 5_CD -_: HT_NNP 
        3_CD Rs_NNP are_VBP clinically_RB efficacious_JJ in_IN the_DT
        treatment_NN of_IN chemotherapy-induced_JJ emesis_NNS [_NN 15_CD ]_NN and_CC recent_JJ
        studies_NNS on_IN human_JJ subjects_NNS have_VBP suggested_VBN their_PRP$ potential_JJ
        application_NN in_IN the_DT treatment_NN of_IN early_JJ onset_NN alcoholism_NN [_NN 16_CD
        17_CD ]_NN ._.
        Hibert_NNP 
        et_CC al_NN proposed_VBD an_DT early_JJ model_NN for_IN the_DT
        antagonist_NN pharmacophore_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN [_NN 18_CD ]_NN ._. According_VBG to_TO this_DT model_NN ,_,
        all_DT 5_CD -_: HT_NNP 
        3_CD R_NN antagonists_NNS contain_VBP an_DT aromatic_JJ
        ring_NN ,_, a_DT carbonyl_NN oxygen_NN or_CC bioisosteric_JJ equivalent_NN ,_, and_CC a_DT
        basic_JJ nitrogen_NN ._. According_VBG to_TO Hibert_NNP 's_POS model_NN ,_, the_DT basic_JJ
        nitrogen_NN is_VBZ located_VBN 5_CD ._. 2_CD A_DT °_NN from_IN the_DT centre_NN of_IN the_DT aromatic_JJ
        ring_NN and_CC approximately_RB 1_CD ._. 7_CD A_DT °_NN above_IN plane_NN of_IN the_DT ring_NN ._. The_DT
        carbonyl_NN oxygen_NN and_CC the_DT aromatic_JJ ring_NN are_VBP coplanar_NN and_CC
        separated_VBN by_IN a_DT distance_NN of_IN 3_CD ._. 3_CD A_DT °_NN ._. Recent_JJ studies_NNS have_VBP
        expanded_VBN on_IN this_DT model_NN to_TO include_VB another_DT lipophilic_JJ region_NN
        and_CC a_DT second_JJ hydrogen_NN bonding_NN interaction_NN two_CD atoms_NNS away_RB
        from_IN the_DT first_JJ [_NN 19_CD 20_CD 21_CD ]_NN ._. A_DT compound_NN that_WDT contains_VBZ all_DT
        five_CD pharmacophoric_JJ regions_NNS was_VBD synthesized_JJ by_IN Orjales_NNP 
        et_CC al_NN [_NN 22_CD ]_NN ._. This_DT compound_NN
        (_( 1_CD -_: (_( phenylmethyl_NN )_) -_: 2_CD -_: piperizinyl_NN benzimidazole_NN or_CC
        lerisetron_NN )_) is_VBZ shown_VBN in_IN figure_NN 1_CD and_CC is_VBZ a_DT potent_JJ 5_CD -_: HT_NNP 
        3_CD R_NN antagonist_NN ._. Functional_NNP groups_NNS on_IN
        this_DT compound_NN capable_JJ of_IN forming_VBG interactions_NNS with_IN the_DT
        receptor_NN are_VBP the_DT distal_NN amino_JJ group_NN ,_, a_DT benzimidazole_NN and_CC a_DT
        benzyl_NN group_NN in_IN the_DT N_NNP 1_CD position_NN of_IN the_DT benzimidazole_NN ._. While_IN
        Lerisetron_NNP contains_VBZ no_DT carbonyl_NN group_NN ,_, the_DT second_JJ nitrogen_NN
        contained_VBD in_IN the_DT benzimidazole_NN heterocycle_NN could_MD act_VB as_IN
        bioisostere_NN of_IN this_DT functional_JJ group_NN [_NN 22_CD ]_NN ._. Orjales_NNP
        demonstrated_VBD the_DT importance_NN of_IN the_DT N-_NNP benzyl_NN group_NN by_IN
        synthesizing_VBG several_JJ N_NNP 1_CD substituted_VBN analogs_NNS of_IN Lerisetron_NNP ._.
        Removal_NNP of_IN the_DT N-_NNP benzyl_NN group_NN produced_VBD a_DT 80_CD -_: fold_VB decrease_VB
        in_IN affinity_NN ,_, indicating_VBG a_DT role_NN for_IN this_DT group_NN in_IN
        interacting_VBG with_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ._. Other_JJ studies_NNS have_VBP supported_VBN this_DT
        observation_NN and_CC suggest_VBP a_DT more_RBR specific_JJ electrostatic_JJ
        interaction_NN [_NN 23_CD ]_NN ._.
        While_IN structure-activity_JJ relationship_NN studies_NNS and_CC
        molecular_JJ modeling_NN have_VBP led_VBN to_TO the_DT development_NN of_IN a_DT
        detailed_VBN pharmacophore_NN model_NN ,_, determining_VBG specific_JJ point_NN
        interactions_NNS between_IN 5_CD -_: HT_NNP 
        3_CD antagonists_NNS and_CC binding_JJ site_NN amino_JJ
        acids_NNS has_VBZ proven_VBN difficult_JJ ._. Mutagenesis_NNP studies_NNS have_VBP
        identified_VBN the_DT interaction_NN of_IN amino_JJ acids_NNS W_NNP 89_CD and_CC R_NN 91_CD in_IN
        the_DT binding_JJ of_IN 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS [_NN 24_CD 23_CD ]_NN ._. Studies_NNPS
        conducted_VBD in_IN our_PRP$ laboratory_NN have_VBP identified_VBN three_CD
        additional_JJ putative_JJ binding_JJ site_NN residues_NNS (_( Y_NNP 140_CD ,_, Y_NNP 142_CD ,_, and_CC
        Y_NNP 152_CD )_) [_NN 25_CD ]_NN ._. W_NNP 89_CD and_CC R_NN 91_CD are_VBP present_JJ in_IN a_DT conserved_JJ
        region_NN of_IN LGIC_NNP receptors_NNS often_RB referred_VBD to_TO as_IN loop_NN D_NNP [_NN 24_CD
        26_CD ]_NN ._. Similarly_RB ,_, Y_NNP 140_CD ,_, Y_NNP 142_CD and_CC Y_NNP 152_CD are_VBP located_VBN in_IN the_DT
        region_NN homologus_JJ to_TO E_NNP loop_NN region_NN of_IN nicotinic_JJ AchR_NNP ._.
        In_IN this_DT study_NN ,_, we_PRP have_VBP endeavoured_JJ to_TO identify_VB the_DT amino_JJ
        acids_NNS interacting_VBG with_IN the_DT different_JJ functional_JJ groups_NNS
        present_JJ on_IN the_DT lerisetron_NN molecule_NN in_IN order_NN to_TO develop_VB a_DT
        model_NN for_IN interaction_NN of_IN this_DT compound_NN with_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ._. Using_VBG site_NN directed_VBD mutagenesis_NNS in_IN
        combination_NN with_IN analogs_NNS of_IN lerisetron_NN ,_, we_PRP have_VBP identified_VBN
        amino_JJ acids_NNS that_WDT appear_VBP to_TO interact_NN selectively_RB with_IN the_DT
        terminal_NN amino_JJ group_NN ,_, the_DT N-_NNP benzyl_NN group_NN and_CC the_DT aromatic_JJ
        benzimidazole_NN ._.
      
      
        Results_NNS
        
          Functional_NNP activity_NN of_IN lerisetron_NN
          Whole_JJ cell_NN patch-clamp_JJ experiments_NNS were_VBD performed_VBN to_TO
          test_VB the_DT functional_JJ activity_NN of_IN lerisetron_NN ._. No_DT response_NN
          was_VBD observed_VBN when_WRB lerisetron_NN was_VBD applied_VBN alone_RB (_( data_NNS not_RB
          shown_VBN )_) ._. When_WRB co-applied_JJ with_IN 5_CD -_: HT_NNP ,_, lerisetron_NN inhibited_VBD
          the_DT absolute_JJ magnitude_NN of_IN the_DT response_NN with_IN no_DT apparent_JJ
          alteration_NN of_IN the_DT response_NN profile_NN (_( Figure_NN 2_LS )_) ._. The_DT
          combination_NN of_IN several_JJ identical_JJ inhibition_NN experiments_NNS
          produced_VBD a_DT K_NNP 
          i_NNP value_NN of_IN 0_CD ._. 2_CD ±_NN 0_CD ._. 03_CD nM_NN for_IN
          lerisetron_NN inhibition_NN of_IN the_DT 5_CD -_: HT_NNP induced_VBD response_NN ._. These_DT
          data_NNS correspond_VB well_RB with_IN previously_RB reported_VBD data_NNS for_IN
          this_DT compound_NN [_NN 22_CD ]_NN and_CC verify_VB the_DT competitive_JJ
          antagonist_NN action_NN of_IN lerisetron_NN ._. Analogs_NNP of_IN lerisetron_NN
          have_VBP been_VBN shown_VBN to_TO inhibit_VB 5_CD -_: HT_NNP 
          3_CD Rs_NNP in_IN a_DT similar_JJ manner_NN [_NN 23_CD ]_NN ._.
        
        
          Importance_NNP of_IN the_DT N-_NNP benzyl_NN and_CC distal_NN piperazine_NN
          nitrogen_NN to_TO binding_JJ of_IN lerisetron_NN
          The_DT K_NNP 
          i_NNP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_NN
          3_CD H_NNP ]_NN -_: granisetron_NN binding_JJ to_TO wildtype_NN receptors_NNS was_VBD
          determined_VBN to_TO be_VB 0_CD ._. 8_CD ±_NN 0_CD ._. 19_CD nM_NN (_( Figure_NN 3_CD and_CC Table_NNP 1_LS )_) ._.
          This_DT value_NN agrees_VBZ with_IN previously_RB published_VBN data_NNS for_IN this_DT
          compound_NN ._. The_DT K_NNP 
          i_NNP values_NNS for_IN analogs_NNS 1_CD and_CC 2_CD under_IN
          identical_JJ conditions_NNS are_VBP 25_CD ±_NN 3_CD ._. 2_CD nM_NN and_CC 320_CD ±_NN 82_CD nM_NN
          respectively_RB (_( Figure_NN 4_CD A_DT ,_, Table_NNP 1_LS )_) ._. The_DT observed_VBN change_NN in_IN
          K_NNP 
          i_NNP represents_VBZ the_DT decreases_NNS in_IN binding_JJ
          energy_NN resulting_VBG from_IN removal_NN of_IN the_DT N-_NNP benzyl_NN group_NN
          (_( analog_NN 1_LS )_) and_CC the_DT distal_NN piperazine_NN nitrogen_NN (_( analog_NN
          2_LS )_) ._.
        
        
          Identification_NNP of_IN amino_JJ acids_NNS interacting_VBG with_IN
          Lerisetron_NNP
          In_IN order_NN to_TO determine_VB the_DT nature_NN of_IN the_DT amino_JJ acids_NNS
          interacting_VBG with_IN the_DT distal_NN amino_JJ and_CC N-_NNP benzyl_NN groups_NNS of_IN
          lerisetron_NN ,_, we_PRP constructed_VBN 5_CD -_: HT_NNP 
          3_CD AS_NNP Rs_NNP containing_VBG mutations_NNS at_IN W_NNP 89_CD ,_,
          R_NN 91_CD ,_, Y_NNP 140_CD ,_, Y_NNP 142_CD and_CC Y_NNP 152_CD ._. Figure_NN 3_CD shows_VBZ inhibition_NN of_IN [_NN
          3_CD H_NNP ]_NN -_: granisetron_NN binding_JJ by_IN lerisetron_NN on_IN wildtype_NN and_CC
          mutant_JJ receptors_NNS ._. For_IN most_JJS amino_JJ acids_NNS ,_, an_DT alanine_NN
          substitution_NN was_VBD constructed_VBN in_IN order_NN to_TO effectively_RB
          remove_VB any_DT amino_JJ acid_NN interaction_NN with_IN the_DT ligand_NN ._. For_IN
          W_NNP 89_CD ,_, an_DT alanine_NN substitution_NN has_VBZ been_VBN shown_VBN to_TO prevent_VB
          binding_JJ of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN ;_: therefore_RB a_DT less_RBR severe_JJ
          mutation_NN was_VBD constructed_VBN ._.
          The_DT W_NNP 89_CD F_NN mutation_NN produces_VBZ a_DT 18_CD -_: fold_VB change_NN in_IN K_NNP 
          d_SYM for_IN [_NN 3_CD H_NNP ]_NN -_: granisetron_NN binding_JJ (_( 18_CD ±_NN
          2_CD nM_NN )_) and_CC the_DT W_NNP 89_CD Y_NNP mutation_NN produces_VBZ a_DT 5_CD ._. 8_CD -_: fold_VB change_NN in_IN
          K_NNP 
          d_SYM (_( 5_CD ._. 7_CD ±_NN 0_CD ._. 7_CD nM_NN )_) ._. Mutation_NNP of_IN amino_JJ
          acid_NN R_NN 91_CD to_TO alanine_NN produced_VBD a_DT 5_CD -_: fold_VB change_NN in_IN K_NNP 
          d_SYM for_IN [_NN 3_CD H_NNP ]_NN granisetron_NN binding_JJ (_( 4_CD ._. 9_CD ±_NN
          0_CD ._. 7_CD nM_NN )_) (_( Table_NNP 1_LS )_) ._. These_DT data_NNS agree_VBP well_RB with_IN previously_RB
          reported_VBD values_NNS [_NN 24_CD ]_NN ._. Alanine_NNP mutations_NNS at_IN the_DT
          tyrosine_NN positions_NNS Y_NNP 140_CD ,_, Y_NNP 142_CD and_CC Y_NNP 152_CD also_RB produced_VBN
          minor_JJ increases_NNS in_IN K_NNP 
          d_SYM for_IN [_NN 3_CD H_NNP ]_NN granisetron_NN binding_JJ (_( 2_CD ._. 7_CD ±_NN
          0_CD ._. 19_CD nM_NN ,_, 4_CD ._. 5_CD ±_NN 0_CD ._. 5_CD nM_NN and_CC 7_CD ._. 8_CD ±_NN 1_CD ._. 1_CD nM_NN respectively_RB )_) [_NN 25_CD
          ]_NN (_( Table_NNP 1_LS )_) ._.
          Only_RB small_JJ changes_NNS in_IN K_NNP 
          i_NNP for_IN lerisetron_NN were_VBD observed_VBN for_IN the_DT
          Y_NNP 140_CD A_DT mutation_NN while_IN the_DT Y_NNP 142_CD A_DT and_CC Y_NNP 152_CD A_DT mutations_NNS
          produced_VBD large_JJ increases_NNS in_IN the_DT K_NNP 
          i_NNP (_( Table_NNP 1_CD and_CC Figure_NN 3_LS )_) ._. For_IN W_NNP 89_CD F_NN and_CC
          W_NNP 89_CD Y_NNP ,_, the_DT changes_NNS in_IN K_NNP 
          i_NNP observed_VBD for_IN lerisetron_NN were_VBD much_RB
          smaller_JJR than_IN for_IN the_DT alanine_NN mutations_NNS at_IN Y_NNP 142_CD A_DT and_CC
          Y_NNP 152_CD A_DT ,_, as_IN would_MD be_VB expected_VBN for_IN the_DT less_RBR severe_JJ nature_NN of_IN
          these_DT mutations_NNS ._. The_DT changes_NNS were_VBD ,_, however_RB significant_JJ (_( p_NN
          <_NN 0_CD ._. 001_CD in_IN both_DT cases_NNS )_) and_CC are_VBP similar_JJ to_TO the_DT changes_NNS
          in_IN K_NNP 
          d_SYM reported_VBD for_IN [_NN 3_CD H_NNP ]_NN granisetron_NN ._. The_DT
          increase_NN in_IN K_NNP 
          i_NNP on_IN the_DT W_NNP 89_CD F_NN mutant_JJ receptor_NN was_VBD 4_CD ._. 8_CD
          ±_NN 0_CD ._. 56_CD fold_VB and_CC the_DT increase_NN in_IN K_NNP 
          i_NNP on_IN the_DT W_NNP 89_CD Y_NNP receptor_NN was_VBD 3_CD ._. 6_CD ±_NN 0_CD ._. 4_CD
          fold_VB ._. The_DT R_NN 91_CD A_DT mutant_JJ produced_VBD an_DT increase_NN in_IN K_NNP 
          i_NNP of_IN 7_CD ._. 6_CD ±_NN 1_CD ._. 5_CD fold_VB as_IN compared_VBN to_TO the_DT
          wildtype_NN receptor_NN ._. These_DT data_NNS indicated_VBD potential_JJ
          interactions_NNS of_IN lerisetron_NN with_IN W_NNP 89_CD ,_, R_NN 91_CD ,_, Y_NNP 142_CD and_CC
          Y_NNP 152_CD ._.
        
        
          Mutation_NNP of_IN W_NNP 89_CD
          As_IN mentioned_VBN above_IN ,_, the_DT lack_NN of_IN [_NN 3_CD H_NNP ]_NN -_: granisetron_NN
          binding_JJ to_TO W_NNP 89_CD A_DT mutant_JJ receptors_NNS necessitated_VBD the_DT use_NN of_IN
          W_NNP 89_CD F_NN and_CC W_NNP 89_CD Y_NNP mutations_NNS to_TO analyze_VB functional_JJ group_NN
          interactions_NNS ._. The_DT effects_NNS of_IN these_DT mutations_NNS on_IN the_DT K_NNP 
          i_NNP for_IN analogs_NNS 1_CD and_CC 2_CD are_VBP shown_VBN in_IN
          figure_NN 4_CD B_NNP ,_, 4_CD Cand_NNP Table_NNP 1_CD ._. Analog_NNP 1_CD inhibited_VBD [_NN
          3_CD H_NNP ]_NN -_: granisetron_NN binding_JJ to_TO W_NNP 89_CD F_NN receptors_NNS with_IN a_DT K_NNP 
          i_NNP of_IN 170_CD ±_NN 54_CD nM_NN (_( 7_CD ±_NN 3_CD ._. 2_CD fold_VB
          increase_NN ,_, p_NN <_NN 0_CD ._. 001_CD )_) and_CC W_NNP 89_CD Y_NNP receptors_NNS with_IN a_DT K_NNP 
          i_NNP of_IN 81_CD ±_NN 14_CD nM_NN (_( 3_CD ._. 2_LS ±_NN 0_CD ._. 6_CD fold_VB
          increase_NN ,_, p_NN <_NN 0_CD ._. 001_CD )_) ._. This_DT reflects_VBZ a_DT significant_JJ
          increase_NN in_IN K_NNP 
          i_NNP and_CC reflects_VBZ a_DT potential_JJ interaction_NN
          of_IN analog_NN 1_CD with_IN W_NNP 89_CD ._. The_DT strength_NN of_IN this_DT interaction_NN is_VBZ
          apparently_RB similar_JJ to_TO the_DT strength_NN of_IN the_DT interaction_NN
          with_IN [_NN 3_CD H_NNP ]_NN -_: granisetron_NN and_CC lerisetron_NN since_IN the_DT magnitude_NN
          of_IN the_DT change_NN is_VBZ similar_JJ in_IN both_DT cases_NNS ._. Analog_NNP 2_CD also_RB
          showed_VBD a_DT significant_JJ increase_NN in_IN K_NNP 
          i_NNP as_IN a_DT result_NN of_IN the_DT W_NNP 89_CD F_NN and_CC W_NNP 89_CD Y_NNP
          mutations_NNS ._. The_DT magnitude_NN of_IN the_DT change_NN for_IN W_NNP 89_CD F_NN (_( 5_CD ._. 1_LS ±_NN
          1_CD ._. 3_CD fold_VB ,_, p_NN <_NN 0_CD ._. 05_CD )_) was_VBD similar_JJ to_TO that_DT observed_VBD for_IN
          lerisetron_NN and_CC analog_NN 1_CD ._. The_DT W_NNP 89_CD Y_NNP mutation_NN produced_VBD a_DT 6_CD ._. 8_CD
          ±_NN 1_CD ._. 6_CD fold_VB change_NN in_IN K_NNP 
          i_NNP (_( p_NN <_NN 0_CD ._. 05_CD )_) ._. Thus_RB ,_, all_DT three_CD
          compounds_NNS appear_VBP to_TO form_VB similar_JJ interactions_NNS with_IN
          W_NNP 89_CD ._.
        
        
          Mutation_NNP of_IN R_NN 91_CD
          Mutation_NNP of_IN R_NN 91_CD to_TO alanine_NN (_( R_NN 91_CD A_DT )_) resulted_VBD in_IN a_DT
          significant_JJ ,_, but_CC small_JJ increase_NN in_IN K_NNP 
          i_NNP for_IN lerisetron_NN of_IN 7_CD ._. 6_CD ±_NN 1_CD ._. 5_CD fold_VB (_( p_NN
          <_NN 0_CD ._. 01_CD )_) ._. Figure_NN 4_CD Dshows_NNP the_DT inhibition_NN of_IN [_NN
          3_CD H_NNP ]_NN -_: granisetron_NN binding_JJ by_IN analogs_NNS 1_CD and_CC 2_CD at_IN R_NN 91_CD A_DT mutant_JJ
          receptors_NNS ._. No_DT significant_JJ change_NN in_IN K_NNP 
          i_NNP was_VBD observed_VBN on_IN these_DT receptors_NNS for_IN
          either_DT analog_NN 1_CD (_( 0_CD ._. 9_CD ±_NN 0_CD ._. 28_CD fold_VB )_) or_CC analog_NN 2_CD (_( 0_CD ._. 56_CD ±_NN
          0_CD ._. 14_CD fold_VB )_) (_( Table_NNP 1_LS )_) as_IN compared_VBN to_TO the_DT wildtype_NN
          receptor_NN ._.
        
        
          Mutation_NNP of_IN Y_NNP 142_CD
          Mutation_NNP of_IN Y_NNP 142_CD to_TO alanine_NN produced_VBD one_CD of_IN the_DT
          largest_JJS observed_VBN changes_NNS in_IN K_NNP 
          i_NNP for_IN lerisetron_NN (_( Figure_NN 3_CD and_CC Table_NNP
          1_LS )_) ._. The_DT K_NNP 
          i_NNP obtained_VBD for_IN lerisetron_NN was_VBD 130_CD ±_NN 28_CD
          nM_NN ,_, reflecting_VBG a_DT change_NN of_IN 160_CD ±_NN 37_CD fold_VB compared_VBN to_TO
          wildtype_NN receptors_NNS ._. The_DT K_NNP 
          i_NNP value_NN for_IN analog_NN 1_CD ,_, in_IN contrast_NN ,_,
          increased_VBD only_RB 6_CD ._. 8_CD ±_NN 2_CD ._. 3_CD fold_VB (_( p_NN <_NN 0_CD ._. 01_CD )_) as_IN a_DT result_NN
          of_IN this_DT mutation_NN (_( Figure_NN 4_CD Eand_NNP Table_NNP 1_LS )_) ._. The_DT K_NNP 
          i_NNP for_IN analog_NN 2_CD showed_VBD a_DT similar_JJ change_NN
          of_IN 17_CD ±_NN 0_CD ._. 77_CD fold_VB (_( p_NN <_NN 0_CD ._. 01_CD )_) ._. While_IN these_DT K_NNP 
          i_NNP values_NNS are_VBP significantly_RB different_JJ
          from_IN wildtype_NN values_NNS for_IN each_DT analog_NN ,_, the_DT lack_NN of_IN larger_JJR
          effects_NNS suggests_VBZ that_IN neither_DT analog_NN 1_CD nor_CC analog_NN 2_CD bind_NN
          as_RB strongly_RB as_IN lerisetron_NN to_TO Y_NNP 142_CD ._.
        
        
          Mutation_NNP of_IN Y_NNP 152_CD
          The_DT Y_NNP 152_CD A_DT mutation_NN showed_VBD the_DT most_JJS variability_NN in_IN its_PRP$
          effects_NNS on_IN K_NNP 
          i_NNP values_NNS for_IN lerisetron_NN ,_, analog_NN 1_CD and_CC
          analog_NN 2_CD (_( Figure_NN 3_CD ,_, Figure_NN 4_CD Fand_NNP Table_NNP 1_LS )_) ._. Lerisetron_NNP
          inhibited_VBD [_NN 3_CD H_NNP ]_NN -_: granisetron_NN binding_VBG with_IN a_DT K_NNP 
          i_NNP value_NN of_IN 150_CD ±_NN 36_CD ;_: an_DT increase_NN of_IN
          190_CD ±_NN 43_CD fold_VB compared_VBN to_TO wildtype_NN values_NNS ._. The_DT K_NNP 
          i_NNP value_NN for_IN analog_NN 1_CD increased_VBN from_IN 25_CD
          ±_NN 3_CD ._. 2_CD nM_NN (_( wildtype_NN )_) to_TO 2_CD ._. 5_CD ±_NN 0_CD ._. 40_CD μM_NN ._. This_DT change_NN of_IN 100_CD
          ±_NN 16_CD fold_VB is_VBZ slightly_RB smaller_JJR ,_, but_CC not_RB significantly_RB
          different_JJ from_IN the_DT relative_JJ change_NN observed_VBD for_IN
          lerisetron_NN ._. The_DT K_NNP 
          i_NNP for_IN analog_NN 2_CD increased_VBN from_IN 0_CD ._. 32_CD ±_NN
          0_CD ._. 08_CD μM_NN on_IN wildtype_NN to_TO 13_CD ±_NN 4_CD ._. 2_CD μM_NN on_IN Y_NNP 152_CD A_DT mutant_JJ
          receptors_NNS (_( 40_CD ±_NN 12_CD fold_VB increase_NN )_) ._. The_DT increase_NN observed_VBD
          for_IN analog_NN 2_CD was_VBD significantly_RB less_JJR than_IN that_DT observed_VBD
          for_IN both_DT lerisetron_NN and_CC analog_NN 1_CD ._. The_DT smaller_JJR change_NN in_IN K_NNP
          
          i_NNS for_IN analog_NN 2_CD suggests_VBZ that_DT analog_NN 2_CD
          binds_NNS weakly_RB to_TO Y_NNP 152_CD while_IN lerisetron_NN and_CC analog_NN 1_CD bind_NN
          more_RBR tightly_RB ._.
        
      
      
        Discussion_NNP
        
          Functional_NNP group_NN interactions_NNS of_IN W_NNP 89_CD
          The_DT W_NNP 89_CD F_NN mutation_NN produced_VBD a_DT significant_JJ increase_NN in_IN K_NNP
          
          i_NNS for_IN all_DT three_CD compounds_NNS ._. The_DT
          magnitude_NN of_IN the_DT change_NN was_VBD similar_JJ in_IN all_DT cases_NNS ._. In_IN
          addition_NN ,_, the_DT increase_NN in_IN K_NNP 
          i_NNP was_VBD identical_JJ to_TO the_DT increase_NN in_IN K_NNP 
          d_SYM that_WDT has_VBZ been_VBN observed_VBN for_IN [_NN
          3_CD H_NNP ]_NN granisetron_NN binding_VBG on_IN this_DT mutant_JJ [_NN 24_CD ]_NN ._.
          Alterations_NNP in_IN K_NNP 
          i_NNP resulting_VBG from_IN the_DT W_NNP 89_CD Y_NNP mutation_NN
          were_VBD slightly_RB less_JJR ,_, however_RB the_DT change_NN was_VBD again_RB the_DT same_JJ
          for_IN lerisetron_NN ,_, analog_NN 1_CD and_CC analog_NN 2_CD ._. These_DT data_NNS suggest_VBP
          that_IN all_DT three_CD compounds_NNS form_VBP binding_JJ site_NN interactions_NNS
          with_IN W_NNP 89_CD ._. The_DT interaction_NN between_IN lerisetron_NN and_CC W_NNP 89_CD is_VBZ
          unlikely_JJ to_TO be_VB via_IN the_DT N-_NNP benzyl_NN functional_JJ group_NN since_IN
          the_DT K_NNP 
          i_NNP for_IN analog_NN 1_CD was_VBD also_RB altered_VBN by_IN
          this_DT mutation_NN ._. The_DT same_JJ argument_NN can_MD be_VB made_VBN for_IN the_DT
          distal_NN piperazine_NN nitrogen_NN since_IN the_DT K_NNP 
          i_NNP for_IN analog_NN 2_CD also_RB increased_VBN ._. The_DT
          portion_NN of_IN the_DT molecule_NN common_JJ to_TO all_DT three_CD compounds_NNS ,_,
          the_DT aromatic_JJ benzimidazole_NN ,_, is_VBZ thus_RB the_DT most_RBS likely_JJ point_NN
          of_IN interaction_NN for_IN W_NNP 89_CD ._.
        
        
          Functional_NNP group_NN interactions_NNS of_IN R_NN 91_CD
          The_DT R_NN 91_CD A_DT mutation_NN increased_VBD the_DT K_NNP 
          i_NNP value_NN for_IN lerisetron_NN inhibition_NN of_IN [_NN
          3_CD H_NNP ]_NN granisetron_NN binding_JJ by_IN 7_CD ._. 6_CD fold_VB ._. This_DT is_VBZ a_DT moderately_RB
          small_JJ change_NN for_IN an_DT alanine_NN mutation_NN ,_, particularly_RB
          considering_VBG that_IN the_DT smallest_JJS change_NN in_IN K_NNP 
          i_NNP for_IN removal_NN of_IN a_DT functional_JJ group_NN on_IN
          lerisetron_NN (_( the_DT N-_NNP benzyl_NN group_NN )_) was_VBD 31_CD fold_VB ._. It_PRP is_VBZ
          therefore_RB likely_JJ that_IN this_DT interaction_NN is_VBZ either_CC
          extremely_RB weak_JJ or_CC the_DT change_NN in_IN K_NNP 
          i_NNP is_VBZ the_DT result_NN of_IN a_DT structural_JJ change_NN
          in_IN the_DT binding_JJ site_NN ._. Previous_JJ studies_NNS concluded_VBD that_DT R_NN 91_CD
          was_VBD an_DT important_JJ interaction_NN for_IN the_DT 5_CD -_: HT_NNP 
          3_CD R_NN agonist_NN 5_CD -_: hydroxytryptamine_NN
          (_( 5_CD -_: HT_NNP )_) ,_, since_IN the_DT K_NNP 
          i_NNP for_IN 5_CD -_: HT_NNP inhibition_NN increased_VBD over_IN
          3000_CD fold_VB as_IN a_DT result_NN of_IN the_DT R_NN 91_CD A_DT mutation_NN [_NN 24_CD ]_NN ._. A_DT
          change_NN in_IN K_NNP 
          d_SYM for_IN [_NN 3_CD H_NNP ]_NN granisetron_NN binding_JJ to_TO R_NN 91_CD A_DT
          was_VBD also_RB observed_VBN ._. In_IN order_NN to_TO determine_VB whether_IN the_DT
          N-_NNP benzyl_NN or_CC distal_NN piperazine_NN nitrogen_NN of_IN lerisetron_NN was_VBD
          involved_VBN in_IN an_DT interaction_NN with_IN R_NN 91_CD ,_, we_PRP tested_VBD both_DT
          analog_NN 1_CD and_CC 2_CD on_IN R_NN 91_CD A_DT mutant_JJ receptors_NNS ._. No_DT change_NN in_IN K_NNP 
          i_NNP was_VBD observed_VBN for_IN either_DT compound_NN ._.
          This_DT result_NN makes_VBZ it_PRP much_RB more_RBR difficult_JJ to_TO assign_VB the_DT
          correct_JJ functional_JJ group_NN to_TO this_DT amino_JJ acid_NN since_IN it_PRP
          suggests_VBZ that_IN one_CD or_CC both_DT of_IN the_DT compounds_NNS is_VBZ no_DT longer_RB
          binding_VBG the_DT receptor_NN in_IN precisely_RB the_DT same_JJ manner_NN as_IN
          lerisetron_NN ._. Considering_VBG the_DT small_JJ change_NN observed_VBD for_IN
          lerisetron_NN binding_VBG as_IN a_DT result_NN of_IN this_DT mutation_NN ,_, even_RB a_DT
          slight_JJ reorientation_NN of_IN the_DT molecule_NN in_IN the_DT binding_JJ site_NN
          could_MD result_VB in_IN the_DT loss_NN of_IN this_DT interaction_NN ._.
        
        
          Functional_NNP group_NN interactions_NNS of_IN Y_NNP 142_CD
          The_DT K_NNP 
          i_NNP values_NNS for_IN inhibition_NN of_IN [_NN
          3_CD H_NNP ]_NN granisetron_NN binding_JJ by_IN analogs_NNS 1_CD and_CC 2_CD were_VBD altered_VBN
          only_RB slightly_RB by_IN the_DT Y_NNP 142_CD A_DT mutation_NN ._. The_DT magnitude_NN of_IN the_DT
          increase_NN in_IN K_NNP 
          i_NNP for_IN lerisetron_NN ,_, however_RB ,_, was_VBD
          considerably_RB larger_JJR (_( 160_CD fold_VB )_) and_CC is_VBZ indicative_JJ of_IN an_DT
          important_JJ interaction_NN of_IN the_DT compound_NN with_IN Y_NNP 142_CD ._. The_DT lack_NN
          of_IN a_DT large_JJ change_NN in_IN K_NNP 
          i_NNP for_IN both_DT analogs_NNS makes_VBZ it_PRP difficult_JJ
          to_TO interpret_VB this_DT data_NNS since_IN one_CD or_CC both_DT of_IN the_DT compounds_NNS
          appears_VBZ to_TO be_VB interacting_VBG differently_RB with_IN the_DT binding_JJ
          site_NN than_IN lerisetron_NN ._.
          Analogs_NNP 1_CD and_CC 2_CD differ_VB from_IN each_DT other_JJ both_DT in_IN the_DT
          functional_JJ groups_NNS contained_VBD in_IN the_DT molecule_NN and_CC their_PRP$
          structural_JJ similarity_NN to_TO lerisetron_NN ._. Analog_NNP 2_CD is_VBZ most_RBS
          similar_JJ in_IN overall_JJ structure_NN ._. The_DT substitution_NN of_IN oxygen_NN
          for_IN the_DT distal_NN amino_JJ nitrogen_NN alters_NNS the_DT potential_JJ
          interactions_NNS formed_VBN at_IN this_DT position_NN ,_, but_CC is_VBZ likely_JJ to_TO
          have_VB a_DT small_JJ effect_NN on_IN the_DT overall_JJ size_NN and_CC shape_NN of_IN the_DT
          molecule_NN ._. Analog_NNP 1_CD is_VBZ far_RB less_RBR similar_JJ to_TO lerisetron_NN and_CC
          more_RBR similar_JJ to_TO the_DT 5_CD -_: HT_NNP 
          3_CD R_NN antagonist_NN granisetron_NN ._. Previous_JJ
          studies_NNS have_VBP shown_VBN that_IN the_DT binding_JJ of_IN granisetron_NN is_VBZ not_RB
          affected_VBN by_IN the_DT Y_NNP 142_CD A_DT mutation_NN [_NN 25_CD ]_NN ._. Analog_NNP 1_CD may_MD bind_NN
          more_RBR similar_JJ to_TO granisetron_NN than_IN lerisetron_NN and_CC thus_RB
          would_MD be_VB unaffected_JJ by_IN mutations_NNS at_IN Y_NNP 142_CD ._. This_DT is_VBZ less_RBR
          likely_JJ to_TO be_VB the_DT case_NN with_IN analog_NN 2_CD ._.
          The_DT strength_NN of_IN the_DT putative_JJ interaction_NN at_IN Y_NNP 142_CD can_MD
          be_VB identified_VBN by_IN examining_VBG the_DT change_NN in_IN binding_JJ of_IN
          lerisetron_NN as_IN a_DT result_NN of_IN the_DT Y_NNP 142_CD A_DT mutation_NN ._. The_DT Y_NNP 142_CD A_DT
          mutation_NN produced_VBD a_DT 160_CD fold_VB change_NN in_IN K_NNP 
          i_NNP ._. This_DT change_NN reflects_VBZ the_DT binding_JJ
          energy_NN lost_VBD as_IN a_DT result_NN of_IN the_DT alanine_NN substitution_NN ._. The_DT
          observed_VBN change_NN in_IN Ki_NNP on_IN wt_NN receptors_NNS is_VBZ much_RB larger_JJR than_IN
          that_DT observed_VBD for_IN removal_NN of_IN the_DT N-_NNP benzyl_NN group_NN (_( 31_CD
          fold_VB )_) ,_, but_CC is_VBZ similar_JJ to_TO that_DT observed_VBD for_IN substitution_NN
          of_IN the_DT distal_NN amino_JJ nitrogen_NN in_IN analog_NN 2_CD (_( 400_CD fold_VB )_) ._.
          Taken_VBN together_RB with_IN the_DT close_JJ structural_JJ similarity_NN of_IN
          analog_NN 2_CD to_TO lerisetron_NN ,_, it_PRP can_MD be_VB concluded_VBN that_DT
          comparison_NN of_IN analog_NN 2_CD and_CC lerisetron_NN should_MD provide_VB the_DT
          best_JJS means_NNS of_IN identifying_VBG the_DT interaction_NN at_IN Y_NNP 142_CD ._. No_DT
          change_NN in_IN K_NNP 
          i_NNP was_VBD observed_VBN for_IN analog_NN 2_CD as_IN a_DT
          result_NN of_IN the_DT Y_NNP 142_CD A_DT mutation_NN indicating_VBG a_DT lack_NN of_IN any_DT
          significant_JJ interaction_NN of_IN this_DT compound_NN with_IN Y_NNP 142_CD ._. These_DT
          data_NNS support_VBP our_PRP$ hypothesis_NNS that_IN Y_NNP 142_CD interacts_NNS with_IN the_DT
          distal_NN piperazine_NN nitrogen_NN of_IN lerisetron_NN ._. A_DT second_JJ amino_JJ
          acid_NN may_MD also_RB be_VB involved_VBN since_IN the_DT change_NN in_IN K_NNP 
          i_NNP for_IN lerisetron_NN binding_VBG as_IN a_DT result_NN
          of_IN the_DT Y_NNP 142_CD A_DT mutation_NN was_VBD smaller_JJR than_IN the_DT change_NN
          produced_VBN by_IN substitution_NN of_IN the_DT piperazine_NN nitrogen_NN ._. As_IN
          described_VBD below_IN ,_, one_CD candidate_NN for_IN this_DT second_JJ amino_JJ acid_NN
          is_VBZ Y_NNP 152_CD ._.
        
        
          Functional_NNP group_NN interactions_NNS of_IN Y_NNP 152_CD
          The_DT Y_NNP 152_CD A_DT mutation_NN produced_VBD increases_NNS in_IN K_NNP 
          i_NNP for_IN all_DT three_CD compounds_NNS although_IN the_DT
          magnitude_NN of_IN the_DT change_NN differed_VBD ._. The_DT increases_NNS in_IN the_DT K_NNP 
          i_NNP values_NNS were_VBD 190_CD fold_VB for_IN lerisetron_NN ,_,
          98_CD fold_VB for_IN analog_NN 1_CD and_CC only_RB 40_CD fold_VB for_IN analog_NN 2_CD ._. Thus_RB ,_,
          analog_NN 1_CD retains_VBZ much_JJ of_IN its_PRP$ ability_NN to_TO interact_NN with_IN
          Y_NNP 152_CD despite_IN the_DT absence_NN of_IN the_DT N-_NNP benzyl_NN group_NN ,_, while_IN
          analog_NN 2_CD interacts_NNS more_RBR weakly_RB with_IN this_DT amino_JJ acid_NN ._.
          Since_IN the_DT K_NNP 
          i_NNP for_IN analog_NN 1_CD is_VBZ increased_VBN by_IN the_DT
          Y_NNP 152_CD A_DT mutation_NN ,_, it_PRP is_VBZ unlikely_JJ that_IN the_DT N-_NNP benzyl_NN group_NN
          interacts_NNS with_IN Y_NNP 152_CD ._. The_DT small_JJ change_NN in_IN K_NNP 
          i_NNP for_IN analog_NN 2_CD supports_VBZ a_DT partial_JJ
          interaction_NN of_IN Y_NNP 152_CD with_IN the_DT distal_NN piperazine_NN nitrogen_NN
          although_IN some_DT interaction_NN with_IN another_DT group_NN is_VBZ also_RB
          apparent_JJ ._. This_DT other_JJ group_NN would_MD be_VB expected_VBN to_TO be_VB in_IN
          close_JJ proximity_NN to_TO the_DT distal_NN nitrogen_NN ._. The_DT most_RBS likely_JJ
          candidate_NN is_VBZ the_DT other_JJ nitrogen_NN of_IN the_DT piperazine_NN ring_NN ._.
          Thus_RB Y_NNP 152_CD A_DT may_MD form_VB a_DT partial_JJ interaction_NN with_IN both_DT
          piperazine_NN nitrogens_NNS ._.
        
      
      
        Conclusions_NNP
        Figure_NN 6_CD shows_VBZ a_DT hypothetical_JJ model_NN of_IN the_DT
        lerisetron-binding_JJ site_NN supported_VBN by_IN our_PRP$ observations_NNS ._. The_DT
        model_NN illustrates_VBZ the_DT secondary_JJ structure_NN of_IN the_DT region_NN of_IN
        the_DT receptor_NN from_IN Y_NNP 140_CD -_: Y_NNP 152_CD in_IN a_DT loop_NN configuration_NN ._. This_DT
        structure_NN is_VBZ supported_VBN by_IN site-directed_JJ mutagenesis_NNS data_NNS [_NN
        25_CD ]_NN as_RB well_RB as_IN structural_JJ predictions_NNS obtained_VBN from_IN other_JJ
        LGIC_NNP receptors_NNS [_NN 31_CD ]_NN ._. The_DT recent_JJ determination_NN of_IN the_DT
        structure_NN of_IN a_DT nicotinic_JJ acetylcholine_NN binding_JJ protein_NN [_NN 27_CD
        ]_NN that_WDT shares_NNS significant_JJ homology_NN with_IN the_DT LGIC_NNP family_NN
        also_RB supports_VBZ a_DT loop_NN structure_NN in_IN this_DT part_NN of_IN the_DT protein_NN ._.
        The_DT region_NN from_IN W_NNP 89_CD through_IN Y_NNP 93_CD is_VBZ shown_VBN as_IN a_DT β-sheet_JJ as_IN
        has_VBZ been_VBN hypothesized_VBN based_VBN on_IN site-directed_JJ mutagenesis_NNS
        studies_NNS of_IN this_DT strand_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN [_NN 24_CD ]_NN ._. Our_PRP$ data_NNS indicate_VBP the_DT
        functional_JJ groups_NNS of_IN lerisetron_NN that_WDT may_MD interact_NN with_IN W_NNP 89_CD ,_,
        R_NN 91_CD ,_, Y_NNP 142_CD and_CC Y_NNP 152_CD ._.
        W_NNP 89_CD is_VBZ shown_VBN interacting_VBG with_IN the_DT aromatic_JJ benzimidazole_NN
        group_NN of_IN lerisetron_NN although_IN the_DT precise_JJ position_NN of_IN W_NNP 89_CD
        relative_JJ to_TO this_DT group_NN is_VBZ not_RB known_VBN ._. The_DT W_NNP 89_CD interaction_NN
        with_IN this_DT group_NN is_VBZ supported_VBN by_IN the_DT observed_VBN increase_NN in_IN K_NNP 
        i_NNP for_IN lerisetron_NN ,_, analog_NN 1_CD and_CC analog_NN 2_CD ._.
        Since_IN the_DT benzimidazole_NN group_NN is_VBZ common_JJ to_TO all_DT three_CD
        compounds_NNS it_PRP is_VBZ the_DT most_RBS likely_JJ point_NN of_IN interaction_NN ._. W_NNP 89_CD
        also_RB represents_VBZ a_DT common_JJ interaction_NN in_IN the_DT binding_JJ site_NN
        for_IN both_DT lerisetron_NN and_CC [_NN 3_CD H_NNP ]_NN granisetron_NN ._.
        Y_NNP 142_CD is_VBZ shown_VBN interacting_VBG with_IN the_DT distal_NN piperazine_NN
        nitrogen_NN possibly_RB through_IN a_DT cation-π_JJ interaction_NN ._. This_DT
        orientation_NN of_IN an_DT amino_JJ group_NN interacting_VBG with_IN an_DT aromatic_JJ
        amino_JJ acid_NN in_IN a_DT cation-π_JJ interaction_NN has_VBZ been_VBN shown_VBN for_IN the_DT
        nicotinic_JJ acetylcholine_NN receptor_NN and_CC has_VBZ been_VBN hypothesized_VBN
        for_IN many_JJ LGIC_NNP receptors_NNS [_NN 28_CD 29_CD 30_CD 26_CD ]_NN ._. This_DT conclusion_NN
        is_VBZ based_VBN on_IN both_DT the_DT magnitude_NN of_IN the_DT change_NN observed_VBD on_IN
        the_DT wild_JJ type_NN receptor_NN for_IN removal_NN of_IN the_DT amino_JJ group_NN (_( 400_CD
        fold_VB )_) compared_VBN to_TO the_DT effect_NN of_IN the_DT Y_NNP 142_CD A_DT mutation_NN on_IN
        lerisetron_NN binding_JJ (_( 160_CD fold_VB )_) and_CC the_DT lack_NN of_IN any_DT major_JJ
        change_NN in_IN K_NNP 
        i_NNP for_IN analog_NN 2_CD as_IN a_DT result_NN of_IN this_DT
        mutation_NN ._. Our_PRP$ data_NNS does_VBZ not_RB support_VB an_DT interaction_NN of_IN this_DT
        amino_JJ acid_NN with_IN either_DT the_DT N-_NNP benzyl_NN or_CC benzimidazole_NN
        portions_NNS of_IN lerisetron_NN ._.
        Y_NNP 152_CD is_VBZ shown_VBN positioned_VBN between_IN the_DT two_CD piperazine_NN
        nitrogens_NNS ._. This_DT conclusion_NN is_VBZ supported_VBN by_IN the_DT smaller_JJR
        increase_NN in_IN K_NNP 
        i_NNP for_IN analog_NN 2_CD (_( 40_CD fold_VB )_) compared_VBN to_TO
        that_DT observed_VBD for_IN lerisetron_NN (_( 190_CD fold_VB )_) ._. These_DT results_NNS
        suggest_VBP a_DT partial_JJ interaction_NN of_IN Y_NNP 152_CD with_IN the_DT distal_NN
        piperazine_NN nitrogen_NN ._. Since_IN some_DT change_NN was_VBD observed_VBN ,_, a_DT
        second_JJ interaction_NN is_VBZ also_RB likely_JJ ._. The_DT functional_JJ group_NN in_IN
        closest_JJS proximity_NN to_TO the_DT distal_NN piperazine_NN nitrogen_NN is_VBZ the_DT
        other_JJ nitrogen_NN on_IN the_DT piperazine_NN ring_NN ._. Another_DT possibility_NN
        would_MD be_VB the_DT N-_NNP benzyl_NN interaction_NN ,_, however_RB ,_, since_IN the_DT Y_NNP 152_CD A_DT
        mutation_NN also_RB produced_VBD a_DT large_JJ increase_NN in_IN K_NNP 
        i_NNP for_IN analog_NN 2_CD ,_, this_DT conclusion_NN is_VBZ not_RB
        supported_VBN by_IN our_PRP$ data_NNS ._.
        R_NN 91_CD is_VBZ shown_VBN as_IN interacting_VBG with_IN the_DT N-_NNP benzyl_NN group_NN ._.
        This_DT is_VBZ a_DT difficult_JJ conclusion_NN to_TO make_VB considering_VBG the_DT
        small_JJ effect_NN of_IN the_DT R_NN 91_CD A_DT mutation_NN on_IN lerisetron_NN binding_JJ ._.
        The_DT interaction_NN is_VBZ included_VBN in_IN the_DT model_NN based_VBN on_IN
        structural_JJ information_NN obtained_VBN from_IN the_DT crystal_NN structure_NN
        of_IN AChBP_NNP [_NN 27_CD ]_NN ._. The_DT region_NN of_IN this_DT protein_NN homologous_RB to_TO
        loop_NN E_NNP and_CC loop_NN D_NNP of_IN the_DT 5_CD -_: HT_NNP 
        3_CD A_DT receptor_NN suggests_VBZ a_DT loop_NN structure_NN
        from_IN Y_NNP 140_CD to_TO Y_NNP 152_CD and_CC a_DT 3_CD -_: residue_NN turn_NN containing_VBG a_DT glycine_NN
        at_IN position_NN 147_CD and_CC the_DT β-strand_JJ from_IN W_NNP 89_CD through_IN Y_NNP 93_CD
        oriented_VBN as_IN shown_VBN in_IN Figure_NN 6_CD ._. The_DT orientation_NN of_IN
        lerisetron_NN between_IN W_NNP 89_CD and_CC Y_NNP 142_CD A_DT as_IN shown_VBN would_MD enable_VB the_DT
        N-_NNP benzyl_NN group_NN to_TO be_VB positioned_VBN in_IN close_JJ proximity_NN to_TO R_NN 91_CD ._.
        If_IN this_DT is_VBZ the_DT case_NN ,_, then_RB a_DT small_JJ alteration_NN in_IN position_NN of_IN
        analog_NN 1_CD or_CC 2_CD in_IN the_DT binding_JJ site_NN could_MD result_VB in_IN the_DT loss_NN
        of_IN this_DT presumably_RB weak_JJ interaction_NN ._. The_DT apparent_JJ
        alterations_NNS in_IN the_DT binding_JJ site_NN location_NN of_IN analog_NN 1_CD would_MD
        be_VB consistent_JJ with_IN this_DT hypothesis_NNS ._. An_DT alternate_JJ hypothesis_NNS
        would_MD place_VB the_DT N-_NNP benzyl_NN group_NN in_IN a_DT different_JJ position_NN ,_,
        interacting_VBG with_IN another_DT amino_JJ acid_NN ;_: either_CC solely_RB or_CC in_IN
        concert_NN with_IN R_NN 91_CD ._.
        Our_PRP$ data_NNS support_VBP a_DT binding_JJ site_NN for_IN lerisetron_NN on_IN the_DT
        5_CD -_: HT_NNP 
        3_CD R_NN that_IN spans_NNS the_DT D_NNP and_CC E_NNP loop_NN regions_NNS ._.
        Table_NNP 2_CD shows_VBZ the_DT sequence_NN alignment_NN for_IN the_DT 5_CD -_: HT_NNP 
        3_CD R_NN ,_, the_DT α_NN 7_CD receptor_NN and_CC the_DT AChBP_NNP for_IN
        these_DT loops_NNS ._. Sequence_NNP alignment_NN of_IN mouse_NN 5_CD -_: HT_NNP 
        3_CD AR_NNP ,_, α_NN 7_CD nAchR_NN and_CC AChBP_NNP result_NN in_IN
        alignment_NN of_IN the_DT proposed_VBN D_NNP and_CC E_NNP loop_NN of_IN the_DT 5_CD -_: HT_NNP 
        3_CD AR_NNP with_IN corresponding_JJ regions_NNS of_IN the_DT
        α_NN 7_CD nAchR_NN and_CC AChBP_NNP ._. The_DT amino_JJ acids_NNS W_NNP 89_CD ,_, R_NN 91_CD Y_NNP 140_CD ,_, Y_NNP 142_CD and_CC
        Y_NNP 152_CD of_IN the_DT 5_CD HT_NNP 
        3_CD A_DT R_NN can_MD be_VB aligned_VBN with_IN W_NNP 53_CD ,_, Q_NNP 55_CD ,_,
        L_NNP 102_CD ,_, R_NN 104_CD ,_, and_CC M_NNP 114_CD of_IN the_DT AChBP_NNP (_( Figure_NN 6_CD )_) ._. These_DT amino_JJ
        acids_NNS form_VBP a_DT cluster_NN in_IN the_DT proposed_VBN acetylcholine_NN binding_JJ
        domain_NN of_IN AChBP_NNP similar_JJ to_TO that_DT proposed_VBD in_IN our_PRP$ model_NN ._. Both_DT
        loops_NNS have_VBP been_VBN identified_VBN on_IN the_DT complementary_JJ face_NN of_IN the_DT
        binding_JJ site_NN of_IN the_DT nAChR_NN ._. It_PRP is_VBZ unknown_JJ if_IN lerisetron_NN
        utilizes_NNS amino_JJ acids_NNS on_IN the_DT principal_JJ face_NN although_IN none_NN
        have_VBP been_VBN identified_VBN ._. The_DT model_NN for_IN lerisetron_NN binding_JJ will_MD
        be_VB further_RBR refined_VBN as_IN its_PRP$ interactions_NNS with_IN other_JJ binding_JJ
        site_NN amino_JJ acids_NNS are_VBP investigated_VBN [_NN 26_CD 32_CD 33_CD ]_NN ._. Of_IN
        particular_JJ interest_NN would_MD be_VB potential_JJ interactions_NNS of_IN the_DT
        N-_NNP benzyl_NN group_NN that_WDT would_MD account_VB for_IN the_DT decrease_NN in_IN
        binding_JJ affinity_NN of_IN analog_NN 2_CD ._. Additional_JJ information_NN gained_VBD
        from_IN comparison_NN of_IN our_PRP$ model_NN with_IN the_DT recent_JJ crystal_NN
        structure_NN of_IN the_DT AChBP_NNP demonstrates_VBZ that_DT lerisetron_NN can_MD be_VB
        roughly_RB '_POS fit_NN '_POS into_IN the_DT binding_JJ site_NN such_JJ that_IN all_PDT the_DT
        residues_NNS line_VBP up_RB as_IN shown_VBN in_IN our_PRP$ model_NN ._. While_IN this_DT is_VBZ not_RB
        direct_JJ evidence_NN that_IN the_DT model_NN is_VBZ correct_JJ ,_, subsequent_JJ
        molecular_JJ modeling_NN of_IN the_DT data_NNS presented_VBN in_IN this_DT paper_NN may_MD
        provide_VB further_JJ support_NN for_IN our_PRP$ hypothesis_NNS ._. Our_PRP$ current_JJ
        model_NN provides_VBZ an_DT initial_JJ working_NN hypothesis_NNS that_WDT can_MD form_VB
        the_DT basis_NN of_IN further_JJ investigation_NN ._. Also_RB ,_, while_IN it_PRP is_VBZ
        unclear_JJ whether_IN the_DT information_NN obtained_VBN in_IN this_DT study_NN can_MD
        be_VB extended_VBN to_TO other_JJ 5_CD -_: HT_NNP 
        3_CD R_NN ligands_NNS ,_, a_DT similar_JJ approach_NN would_MD be_VB
        useful_JJ in_IN identifying_VBG functional_JJ group_NN interactions_NNS for_IN
        mCPBG_NN ,_, 5_CD -_: HT_NNP ,_, dtC_NN and_CC granisetron_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Mutagenesis_NNP
          Wild_NNP type_NN 5_CD -_: HT_NNP 
          3_CD AS_NNP mouse_NN receptor_NN cDNA_NN was_VBD derived_VBN
          from_IN N_NNP 1_CD E-_NNP 115_CD neuroblastoma_NN cells_NNS as_RB previously_RB described_VBD
          [_NN 24_CD ]_NN ._. Mutant_NNP receptors_NNS were_VBD constructed_VBN using_VBG
          polymerase_NN chain_NN reaction_NN (_( Quick_NNP change_NN mutagenesis_NNS kit_NN ,_,
          Promega_NNP )_) ._. All_DT mutations_NNS were_VBD confirmed_VBN by_IN DNA_NNP
          sequencing_VBG ._.
        
        
          Cell_NNP culture_NN methods_NNS and_CC transfections_NNS
          tsA_NN 201_CD cells_NNS (_( a_DT derivative_NN of_IN the_DT HEK_NNP 293_CD cell_NN line_NN )_)
          were_VBD grown_VBN in_IN Dulbecco_NNP 's_POS modified_VBN Eagles_NNPS medium_NN (_( D-MEM_NNP )_)
          containing_VBG 10_CD %_NN FBS_NNP and_CC 100_CD -_: units_NNS /_NN ml_NN
          penicillin_NN /_NN streptomycin_NN ._. Cultures_NNP were_VBD maintained_VBN in_IN
          humidified_JJ atmosphere_NN of_IN 5_CD %_NN CO_NNP 
          2_CD at_IN 37_CD °_NN C_NNP ._. For_IN binding_JJ studies_NNS ,_, tsA_NN 201_CD
          cells_NNS were_VBD plated_JJ at_IN a_DT density_NN of_IN 5_CD ×_NN 10_CD 6_CD cells_NNS /_NN 75_CD cm_NN
          2_CD and_CC grown_VBN for_IN 9_CD hours_NNS prior_RB to_TO transfection_NN ._. Cells_NNP were_VBD
          transfected_JJ with_IN 10_CD μg_NN murine_NN 5_CD -_: HT_NNP 
          3_CD AS_NNP R_NNP cDNA_NN using_VBG calcium_NN phosphate_NN
          co-precipitation_JJ (_( New_NNP Life_NNP Technologies_NNPS ,_, NY_NNP )_) ,_, then_RB
          incubated_JJ 36_CD hours_NNS prior_RB to_TO harvesting_NN ._. For_IN whole_JJ cell_NN
          patch_NN clamp_NN experiments_NNS ,_, tsA_NN 201_CD cells_NNS were_VBD plated_JJ at_IN a_DT
          density_NN of_IN 0_CD ._. 25_CD ×_NN 10_CD 6_CD cells_NNS /_NN 27_CD cm_NN 2_CD dish_NN and_CC grown_VBN 12_CD
          hours_NNS prior_RB to_TO transfection_NN ._. Cells_NNP were_VBD washed_VBN with_IN fresh_JJ
          culture_NN medium_NN then_RB transfected_JJ with_IN 10_CD μg_NN 5_CD -_: HT_NNP 
          3_CD AS_NNP R_NNP cDNA_NN using_VBG Qiagen_NNP Superfect_NNP
          transfection_NN reagent_NN (_( Qiagen_NNP ,_, CA_NNP )_) ._. Transfected_NNP cells_NNS were_VBD
          incubated_JJ with_IN this_DT mixture_NN for_IN 2_CD ._. 5_CD hours_NNS ,_, then_RB divided_VBN
          into_IN 35_CD mm_NN culture_NN dishes_NNS at_IN a_DT density_NN of_IN approximately_RB 5_CD
          ×_NN 10_CD 4_CD cells_NNS /_NN dish_NN and_CC incubated_JJ for_IN 24_CD hours_NNS at_IN 37_CD °_NN C_NNP
          before_IN recording_VBG ._.
        
        
          Radioligand_NNP Binding_NNP Assay_NNP
          Transfected_NNP cells_NNS were_VBD scraped_JJ from_IN the_DT dishes_NNS ,_, washed_VBD
          twice_RB with_IN Dulbecco_NNP 's_POS PBS_NNP (_( New_NNP Life_NNP Technologies_NNPS ,_, NY_NNP )_) ,_,
          then_RB resuspended_JJ in_IN 1_CD ._. 0_CD ml_NN PBS_NNP /_NN 100_CD mm_NN dish_NN ._. Cells_NNP were_VBD
          either_CC used_VBN fresh_JJ or_CC frozen_VBN at_IN this_DT step_NN until_IN needed_VBN ._.
          Immediately_RB prior_RB to_TO use_VB ,_, cells_NNS were_VBD homogenized_JJ in_IN PBS_NNP
          using_VBG a_DT glass_NN tissue_NN homogenizer_NN then_RB centrifuged_JJ at_IN 35_CD
          000_CD ×_NN g_SYM for_IN 30_CD minutes_NNS in_IN a_DT Beckman_NNP JA_NNP 20_CD rotor_NN ._. Membranes_NNP
          were_VBD washed_VBN once_RB more_JJR with_IN PBS_NNP then_RB resuspended_JJ in_IN 1_CD ml_NN
          PBS_NNP /_NN 100_CD mm_NN dish_NN ._. Protein_NNP content_NN was_VBD determined_VBN using_VBG a_DT
          Lowry_NNP assay_NN (_( Sigma_NNP ._. Diagnostics_NNPS ,_, St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._. Binding_NNP
          assays_NNS were_VBD performed_VBN in_IN PBS_NNP ._. For_IN K_NNP 
          d_SYM determinations_NNS ,_, 100_CD μl_NN of_IN homogenate_NN
          was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 1_CD hour_NN with_IN varying_VBG
          concentrations_NNS of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN (_( NEN_NNP ,_, MA_NNP )_) ._. Specific_JJ
          binding_JJ of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN was_VBD determined_VBN as_IN the_DT bound_VBN
          [_NN 3_CD H_NNP ]_NN granisetron_NN not_RB displaced_VBN by_IN a_DT saturating_VBG
          concentration_NN of_IN a_DT competing_VBG ligand_NN (_( 100_CD μM_NN mCPBG_NN or_CC 10_CD
          μM_NN MDL-_NNP 72222_CD )_) ._. K_NNP 
          d_SYM values_NNS were_VBD determined_VBN by_IN fitting_JJ
          the_DT binding_JJ data_NN to_TO the_DT following_VBG equation_NN using_VBG GraphPad_NNP
          PRISM_NNP (_( San_NNP Diego_NNP CA_NNP )_) :_: B_NNP =_SYM Bmax_NNP [_NN L_NNP ]_NN n_NN /_NN (_( [_NN L_NNP ]_NN n_NN +_NN Kn_NNP )_) ,_,
          where_WRB θ_NN is_VBZ bound_VBN ligand_NN ,_, Bmax_NNP is_VBZ the_DT maximum_NN binding_JJ at_IN
          equilibrium_NN L_NNP is_VBZ the_DT free_JJ ligand_NN concentration_NN and_CC n_NN is_VBZ
          the_DT Hill_NNP coefficient_NN ._. For_IN K_NNP 
          i_NNP determinations_NNS ,_, 100_CD μl_NN of_IN homogenate_NN
          was_VBD incubated_JJ at_IN 37_CD °_NN C_NNP for_IN 2_CD hours_NNS with_IN varying_VBG
          concentrations_NNS of_IN inhibitor_NN and_CC [_NN 3_CD H_NNP ]_NN granisetron_NN (_( NEN_NNP ,_,
          MA_NNP )_) ._. Binding_NNP was_VBD terminated_VBN by_IN rapid_JJ filtration_NN onto_IN a_DT
          GF_NNP /_NN B_NNP filters_NNS ._. The_DT IC_NNP 
          50_CD values_NNS were_VBD calculated_VBN by_IN fitting_JJ
          the_DT data_NNS to_TO the_DT following_VBG equation_NN using_VBG GraphPad_NNP PRISM_NNP
          (_( San_NNP Diego_NNP CA_NNP )_) :_: θ_NN =_SYM 1_CD /_NN (_( 1_CD +_NN (_( L_NNP /_NN IC_NNP 
          50_CD )_) )_) ,_, where_WRB θ_NN is_VBZ the_DT fractional_JJ
          amount_NN of_IN [_NN 3_CD H_NNP ]_NN granisetron_NN bound_VBN in_IN the_DT presence_NN of_IN
          inhibitor_NN at_IN concentration_NN L_NNP as_IN compared_VBN to_TO the_DT amount_NN of_IN
          [_NN 3_CD H_NNP ]_NN granisetron_NN bound_VBN in_IN the_DT absence_NN of_IN inhibitor_NN ._. IC_NNP 
          50_CD is_VBZ the_DT concentration_NN at_IN which_WDT θ_NN =_SYM
          0_CD ._. 5_CD ._. The_DT K_NNP 
          i_NNP is_VBZ calculated_VBN from_IN the_DT IC_NNP 
          50_CD value_NN using_VBG the_DT Cheng-_NNP Prusoff_NNP
          equation_NN ._.
        
        
          Electrophysiological_NNP Methods_NNP
          Transfected_NNP tsA_NN 201_CD cells_NNS were_VBD transferred_VBN to_TO a_DT
          recording_NN chamber_NN and_CC submerged_JJ in_IN extracellular_NN
          recording_NN buffer_NN containing_VBG 25_CD mM_NN HEPES_NNP pH_NN 7_CD ._. 4_CD ,_, 140_CD mM_NN
          NaCl_NNP ,_, 1_CD ._. 7_CD mM_NN MgCl_NNP 
          2_CD ,_, 5_CD mM_NN KCl_NNP ,_, 1_CD ._. 8_CD mM_NN CaCl_NNP 
          2_CD ._. Patch_NNP electrodes_NNS (_( 2_CD -_: 2_CD ._. 5_LS MΩ_NNP )_) were_VBD
          filled_VBN with_IN intracellular_NN recording_NN buffer_NN containing_VBG 25_CD
          mM_NN HEPES_NNP pH_NN 7_CD ._. 4_CD ,_, 145_CD mM_NN KCL_NNP ,_, 2_CD mM_NN MgCl_NNP 
          2_CD and_CC 1_CD mM_NN EGTA_NNP ._. Cells_NNP were_VBD clamped_VBN in_IN
          whole_JJ cell_NN configuration_NN at_IN a_DT holding_VBG potential_NN of_IN -_: 60_CD
          mV_NN ._. Currents_NNP elicited_JJ by_IN agonist_NN application_NN were_VBD
          measured_VBN using_VBG an_DT Axopatch_NNP 200_CD B_NNP amplifier_NN (_( Foster_NNP City_NNP ,_,
          CA_NNP )_) under_IN computer_NN control_NN (_( DataPac_NNP 2000_CD ,_, RUN_NNP
          Technologies_NNPS )_) ._. Agonists_NNP and_CC antagonists_NNS were_VBD dissolved_VBN in_IN
          extracellular_NN solution_NN and_CC delivered_VBN to_TO cells_NNS using_VBG a_DT
          rapid_JJ perfusion_NN system_NN (_( Warner_NNP Instruments_NNP ,_, Hamden_NNP ,_, CT_NNP )_) ._.
          For_IN EC_NNP 
          50_CD determinations_NNS ,_, responses_NNS were_VBD
          normalized_JJ to_TO the_DT maximum_NN response_NN obtained_VBN from_IN the_DT full_JJ
          agonist_NN 5_CD -_: HT_NNP and_CC fitted_JJ to_TO the_DT equation_NN Ψ_NN =_SYM 1_CD /_NN 1_CD +_NN (_( EC_NNP 50_CD /_NN [_NN C_NNP ]_NN
          n_NN )_) ,_, where_WRB Ψ_NN is_VBZ the_DT normalized_JJ current_NN at_IN 5_CD -_: HT_NNP
          concentration_NN [_NN C_NNP ]_NN ,_, EC_NNP 50_CD is_VBZ the_DT concentration_NN of_IN 5_CD -_: HT_NNP
          needed_VBD to_TO obtain_VB half_JJ maximal_NN activation_NN and_CC n_NN is_VBZ the_DT
          apparent_JJ Hill_NNP coefficient_NN ._. For_IN inhibition_NN experiments_NNS ,_,
          cells_NNS were_VBD exposed_VBN to_TO inhibitor_NN alone_RB for_IN 30_CD s_VBZ prior_RB to_TO
          co-exposure_JJ with_IN 5_CD -_: HT_NNP ._. Inhibited_NNP responses_NNS were_VBD
          calculated_VBN as_IN a_DT fraction_NN of_IN the_DT response_NN to_TO 5_CD -_: HT_NNP alone_RB ._.
          Data_NNP were_VBD plotted_VBD as_IN the_DT fractional_JJ response_NN versus_CC the_DT
          concentration_NN of_IN inhibitor_NN and_CC analysed_JJ using_VBG GraphPad_NNP
          software_NN ._. The_DT IC_NNP 
          50_CD value_NN was_VBD calculated_VBN as_IN the_DT
          concentration_NN of_IN antagonist_NN inhibiting_VBG the_DT 5_CD -_: HT_NNP evoked_JJ
          response_NN by_IN 50_CD %_NN ._. A_DT K_NNP 
          i_NNP value_NN was_VBD calculated_VBN from_IN the_DT IC_NNP 
          50_CD using_VBG the_DT Cheng-_NNP Prusoff_NNP
          equation_NN ._.
        
        
          Synthesis_NNP of_IN Lerisetron_NNP and_CC its_PRP$ analogs_NNS
          All_DT target_NN molecules_NNS were_VBD prepared_VBN according_VBG to_TO a_DT
          general_JJ 2_CD -_: step_NN synthesis_NN reported_VBD previously_RB by_IN Orjales_NNP 
          et_CC al_NN ._. with_IN only_RB slight_JJ
          modification_NN [_NN 22_CD 23_CD ]_NN ._. Commercially_NNP available_JJ
          2_CD -_: chlorobenzimidazole_NN ,_, in_IN dry_JJ DMF_NNP was_VBD treated_VBN with_IN a_DT
          slight_JJ excess_NN of_IN NaH_NNP ,_, (_( 1_CD ._. 1_LS eq_NN )_) ._. After_IN stirring_VBG for_IN 1_CD hour_NN
          at_IN room_NN temperature_NN ,_, one_CD equivalent_NN of_IN the_DT appropriate_JJ
          alkyl_NN bromide_NN was_VBD added_VBN slowly_RB and_CC the_DT reaction_NN mixture_NN
          heated_JJ under_IN reflux_NN for_IN >_NN 5_CD hours_NNS (_( the_DT reaction_NN was_VBD
          monitored_VBN by_IN TLC_NNP )_) ._. Reaction_NNP product_NN was_VBD partitioned_JJ
          between_IN water_NN and_CC methylene_NN chloride_NN ;_: organic_JJ layer_NN was_VBD
          dried_VBN (_( Na_NNP 
          2_CD SO_NNP 
          4_LS )_) and_CC concentrated_VBN in_IN vacuum_NN ._. The_DT
          solid_JJ residue_NN was_VBD purified_JJ by_IN Flash_NNP chromatography_NN ,_, which_WDT
          afforded_VBN the_DT corresponding_JJ N-_NNP substituted_VBD
          2_CD -_: Chlorobenzimidazole_NNP intermediates_NNS in_IN good_JJ yield_NN ._. The_DT
          final_JJ step_NN involved_VBD a_DT nucleophilic_JJ substitution_NN of_IN the_DT
          2_CD -_: chloro_NN group_NN by_IN piperazine_NN at_IN high_JJ temperatures_NNS ._. The_DT
          reaction_NN was_VBD performed_VBN neat_JJ using_VBG 4_CD -_: 10_CD fold_VB excess_JJ
          piperazine_NN and_CC typically_RB heated_JJ for_IN a_DT short_JJ period_NN only_RB ,_,
          (_( 30_CD -_: 45_CD min_NN )_) ._. Similar_JJ work-up_JJ afforded_VBN a_DT residue_NN that_WDT was_VBD
          purified_JJ by_IN either_DT crystallization_NN or_CC chromatography_NN ._. The_DT
          yields_NNS ranged_VBD from_IN 40_CD -_: 95_CD %_NN ._. All_DT compounds_NNS were_VBD
          characterized_VBN by_IN NMR_NNP ,_, MS_NNP ,_, HRMS_NNP ,_, and_CC /_NN or_CC elemental_NN
          analysis_NN or_CC were_VBD identical_JJ to_TO literature_NN reports_NNS ._.
        
        
          Materials_NNS
          D-MEM_NNP ,_, Penicillin-_NNP Streptomycin_NNP ,_, fetal_JJ bovine_JJ serum_NN ,_,
          and_CC Trypsin_NNP were_VBD obtained_VBN from_IN New_NNP Life_NNP Technologies_NNPS ._.
          5_LS -_: HT_NNP and_CC MDL-_NNP 72222_CD were_VBD obtained_VBN from_IN RBI_NNP ._. [_NN
          3_CD H_NNP ]_NN -_: granisetron_NN (_( 84_CD Ci_NNP /_NN mmol_NN )_) was_VBD purchased_VBN from_IN New_NNP
          England_NNP Nuclear_NNP ._.
        
      
    
  
